<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; WisdomTree Dreyfus Euro</title>
	<atom:link href="http://www.stockbloghub.com/tag/wisdomtree-dreyfus-euro/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(EU) Foreign Banks Stock Update &#8211; March 2012 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2012/02/29/eu-foreign-banks-stock-update-march-2012-industry-outlook/93840</link>
		<comments>http://www.stockbloghub.com/2012/02/29/eu-foreign-banks-stock-update-march-2012-industry-outlook/93840#comments</comments>
		<pubDate>Thu, 01 Mar 2012 05:53:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Banco Bradesco S.A.]]></category>
		<category><![CDATA[Banco de Chile]]></category>
		<category><![CDATA[Banco Latinoamericano de Exportaciones SA]]></category>
		<category><![CDATA[Banco Macro S.A.]]></category>
		<category><![CDATA[Banco Santander S.a.]]></category>
		<category><![CDATA[Banco Santander-Chile]]></category>
		<category><![CDATA[Bancolombia S.A.]]></category>
		<category><![CDATA[Bank of Montreal]]></category>
		<category><![CDATA[BAP]]></category>
		<category><![CDATA[Barclays plc]]></category>
		<category><![CDATA[BBD]]></category>
		<category><![CDATA[BBVA Banco Frances S.A.]]></category>
		<category><![CDATA[BCH]]></category>
		<category><![CDATA[BCS]]></category>
		<category><![CDATA[BFR]]></category>
		<category><![CDATA[BLX]]></category>
		<category><![CDATA[BMA]]></category>
		<category><![CDATA[BMO]]></category>
		<category><![CDATA[BNS]]></category>
		<category><![CDATA[Canadian Imperial Bank of Commerce]]></category>
		<category><![CDATA[CIB]]></category>
		<category><![CDATA[CM]]></category>
		<category><![CDATA[Credicorp Limited]]></category>
		<category><![CDATA[Credit Suisse Group]]></category>
		<category><![CDATA[CS]]></category>
		<category><![CDATA[DB]]></category>
		<category><![CDATA[Deutsche Bank AG]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HBC]]></category>
		<category><![CDATA[HDB]]></category>
		<category><![CDATA[HDFC Bank Limited]]></category>
		<category><![CDATA[HSBC HLDGS PLC ADS]]></category>
		<category><![CDATA[IBN]]></category>
		<category><![CDATA[ICICI Bank Limited]]></category>
		<category><![CDATA[Itau Unibanco Holding Sa]]></category>
		<category><![CDATA[ITUB]]></category>
		<category><![CDATA[KB]]></category>
		<category><![CDATA[Kookmin Bank]]></category>
		<category><![CDATA[Lloyds Banking Group plc]]></category>
		<category><![CDATA[LYG]]></category>
		<category><![CDATA[MFG]]></category>
		<category><![CDATA[Mitsubishi UFJ Financial Group Inc]]></category>
		<category><![CDATA[Mizuho Financial Group Inc.]]></category>
		<category><![CDATA[MTU]]></category>
		<category><![CDATA[National Bank of Greece SA]]></category>
		<category><![CDATA[NBG]]></category>
		<category><![CDATA[Royal Bank of Canada]]></category>
		<category><![CDATA[RY]]></category>
		<category><![CDATA[SAN]]></category>
		<category><![CDATA[SHG]]></category>
		<category><![CDATA[Shinhan Financial Group Company Limited]]></category>
		<category><![CDATA[STD]]></category>
		<category><![CDATA[TD]]></category>
		<category><![CDATA[The Bank Of Nova Scotia]]></category>
		<category><![CDATA[Toronto-Dominion Bank]]></category>
		<category><![CDATA[UBS]]></category>
		<category><![CDATA[UBS AG]]></category>
		<category><![CDATA[WBK]]></category>
		<category><![CDATA[Westpac Banking Corporation]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=93840</guid>
		<description><![CDATA[Foreign banks have been facing difficulties non-stop since the latest financial crisis, which triggered off as a credit issue in the sub-prime enclave of the U.S. mortgage market in mid-2007, and spilled all over the globe. The latest deterrents –– nagging macroeconomic issues, the European sovereign debt crisis in particular, and regulatory pressure –– also resulted in the sector’s latest under-performance. Moreover, the upcoming quarters look even worse with several negatives like asset-quality troubles, weak revenue growth, steeper costs and weak loan demand. But thanks to the worldwide regulatory reform, the sector has at least entered a transformation phase. Needless to mention, a change is yet to be felt. The sector entered 2012 with a lot less momentum than anticipated. Rising concerns related to funding and limited access to market ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/29/eu-foreign-banks-stock-update-march-2012-industry-outlook/93840/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Chemical Industry Stock Outlook &#8211; January 2012 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2012/01/25/eu-chemical-industry-stock-outlook-january-2012-industry-outlook/90763</link>
		<comments>http://www.stockbloghub.com/2012/01/25/eu-chemical-industry-stock-outlook-january-2012-industry-outlook/90763#comments</comments>
		<pubDate>Wed, 25 Jan 2012 18:01:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[ACC]]></category>
		<category><![CDATA[American Campus Communities Inc]]></category>
		<category><![CDATA[BAK]]></category>
		<category><![CDATA[Basf Se]]></category>
		<category><![CDATA[BASFY]]></category>
		<category><![CDATA[Braskem S.A.]]></category>
		<category><![CDATA[Calgon Carbon Corporation]]></category>
		<category><![CDATA[CCC]]></category>
		<category><![CDATA[CE]]></category>
		<category><![CDATA[Celanese Corporation]]></category>
		<category><![CDATA[DD]]></category>
		<category><![CDATA[DOW]]></category>
		<category><![CDATA[Eastman Chemical Company]]></category>
		<category><![CDATA[EI DuPont de Nemours & Company]]></category>
		<category><![CDATA[EMN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Exxon Mobil Corporation]]></category>
		<category><![CDATA[Mitsubishi UFJ Financial Group Inc]]></category>
		<category><![CDATA[MTU]]></category>
		<category><![CDATA[PPG]]></category>
		<category><![CDATA[PPG Industries Inc.]]></category>
		<category><![CDATA[The Dow Chemical Company]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[XOM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90763</guid>
		<description><![CDATA[Chemicals are generally used to make a wide variety of consumer goods and are also in the agriculture, manufacturing, construction and service industries. The chemical industry itself consumes 26% of its own output. Major industrial customers include rubber and plastic products, textiles, apparel, petroleum refining, pulp and paper, and primary metals. The chemical industry has shown rapid growth for more than fifty years. The fastest-growing areas have involved the manufacture of synthetic organic polymers used as plastics, fibers and elastomers. Globally, the chemical industry is mainly concentrating in three areas of the world: Western Europe, North America and Japan. Europe is the largest producer, followed by the U.S. and Japan. Chemicals are a nearly $3 trillion global business, and the European Union (EU) and U.S. chemical companies are the world&#8217;s ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/25/eu-chemical-industry-stock-outlook-january-2012-industry-outlook/90763/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(XLE) Stock Market News for January 24, 2012 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2012/01/24/xle-stock-market-news-for-january-24-2012-market-news/90720</link>
		<comments>http://www.stockbloghub.com/2012/01/24/xle-stock-market-news-for-january-24-2012-market-news/90720#comments</comments>
		<pubDate>Tue, 24 Jan 2012 17:19:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[APA]]></category>
		<category><![CDATA[Apache Corporation]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[Cabot Oil & Gas Corporation]]></category>
		<category><![CDATA[Chesapeake Energy Corporation]]></category>
		<category><![CDATA[CHK]]></category>
		<category><![CDATA[CNX]]></category>
		<category><![CDATA[COG]]></category>
		<category><![CDATA[CONSOL Energy Inc]]></category>
		<category><![CDATA[Energy Select Sector SPDR]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[GOOG]]></category>
		<category><![CDATA[Google Inc.]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[IMF]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[International Business Machines]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[Southwestern Energy Company]]></category>
		<category><![CDATA[SWN]]></category>
		<category><![CDATA[Western Asset Inflation Management Fund Inc]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[XLE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90720</guid>
		<description><![CDATA[Markets hovered around break-even levels on Monday as encouragement from the energy sector balanced apprehensions over Greece’s debt negotiations. With no major economic data or earnings results from any bellwether coming to forefront, benchmarks took a pause a day ahead of Apple’s results. The Dow Jones Industrial Average (DJI) dropped 0.1% to close the day at 12,708.82. The Standard &#38; Poor 500 (S&#38;P 500) was up 0.05% and settled almost unchanged at 1,316. The Nasdaq Composite Index edged down 0.09% and finished trading for the day at 2,784.17. The fear-gauge CBOE Volatility Index ended slightly higher at 18.67. On the New York Stock Exchange, NYSE Amex and Nasdaq, consolidated volumes were roughly 6.6 billion shares, almost flat compared to the daily average of 6.68 billion shares. For every couple of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/24/xle-stock-market-news-for-january-24-2012-market-news/90720/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) ViroPharma  Drug Earns Priority Review</title>
		<link>http://www.stockbloghub.com/2012/01/16/vphm-viropharma-drug-earns-priority-review/90265</link>
		<comments>http://www.stockbloghub.com/2012/01/16/vphm-viropharma-drug-earns-priority-review/90265#comments</comments>
		<pubDate>Mon, 16 Jan 2012 23:37:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90265</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) recently announced that the Canadian regulatory body has granted priority review status to the company’s new drug submission (NDS) for Cinryze. ViroPharma is seeking the drug’s approval for the treatment of prevention, pre-procedure prevention, and treatment of attacks of hereditary angioedema (HAE) in patients who are six years or older. The company expects Health Canada to complete its review of Cinryze in the second half of 2012. We note that Cinryze is currently marketed in the US for the prevention of angioedema attacks in adolescent and adult patients with HAE. In the European Union (EU), the same drug is marketed for the treatment of prevention, pre-procedure prevention, and treatment of attacks of HAE in adolescents and adult patients. We view this development as a positive for ViroPharma, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/16/vphm-viropharma-drug-earns-priority-review/90265/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Stock Market News for January 16, 2012 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2012/01/16/eu-stock-market-news-for-january-16-2012-market-news/90261</link>
		<comments>http://www.stockbloghub.com/2012/01/16/eu-stock-market-news-for-january-16-2012-market-news/90261#comments</comments>
		<pubDate>Mon, 16 Jan 2012 23:35:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[AA]]></category>
		<category><![CDATA[Alcoa Inc.]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Financial Select Sector SPDR]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[XLF]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90261</guid>
		<description><![CDATA[Markets edged lower once again, bogged down by cross-Atlantic concerns as several euro-zone countries looked likely to suffer credit-rating downgrades. Things were also farm from cheerful on the domestic front after banking major J.P. Morgan Chase dampened sentiment with its quarterly results. These concerns mingled to partially erode weekly gains, but benchmarks were eventually able to hold on to gains for the week. The Dow Jones Industrial Average (DJI) shed 0.4% to end the day at 12,422.06. The Standard &#38; Poor 500 (S&#38;P 500) was down 0.5% and closed Friday’s trading session at 1,289.09. The Nasdaq Composite Index slipped 0.5% and finished at 2,710.67. The fear-gauge CBOE Volatility Index (VIX) moved up by 2.2% and settled at 20.91. Nonetheless, the fear-gauge index is still well below the key level of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/16/eu-stock-market-news-for-january-16-2012-market-news/90261/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Stock Market News for January 12, 2012 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2012/01/13/eu-stock-market-news-for-january-12-2012-market-news/90067</link>
		<comments>http://www.stockbloghub.com/2012/01/13/eu-stock-market-news-for-january-12-2012-market-news/90067#comments</comments>
		<pubDate>Fri, 13 Jan 2012 21:01:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[AA]]></category>
		<category><![CDATA[AK Steel Holding Corporation]]></category>
		<category><![CDATA[AKS]]></category>
		<category><![CDATA[Alcoa Inc.]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[FCX]]></category>
		<category><![CDATA[Freeport-McMoRan Copper & Gold Inc]]></category>
		<category><![CDATA[Materials Select Sector SPDR]]></category>
		<category><![CDATA[NEM]]></category>
		<category><![CDATA[Newmont Mining Corporation]]></category>
		<category><![CDATA[Nucor Corporation]]></category>
		<category><![CDATA[NUE]]></category>
		<category><![CDATA[US Gold Corporation]]></category>
		<category><![CDATA[UXG]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[XLB]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90067</guid>
		<description><![CDATA[European debt concerns once again weighed down the markets and dragged the Dow slightly lower, while the S&#38;P 500 and Nasdaq posted meager gains. Reports of Germany’s economy contracting during the end of 2011 and a downward revision of economic growth estimates by the European Union (EU) dented the markets. However, a late upward swing helped the markets extend their stay around five-month high levels. The Dow Jones Industrial Average (DJI) dropped 0.1% to settle at 12,449.45. The Standard &#38; Poor 500 (S&#38;P 500) edged up by a mere 0.03% to finish yesterday’s trading session at 1,292.48. The Nasdaq Composite Index added 0.3% to close at 2,710.76. The fear-gauge CBOE Volatility Index (VIX) rose 1.7% to settle at 21.05. On the New York Stock Exchange, NYSE Amex and Nasdaq, consolidated ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/13/eu-stock-market-news-for-january-12-2012-market-news/90067/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ITMN) InterMune Fourth Quarter Esbriet Sales Snapshot</title>
		<link>http://www.stockbloghub.com/2012/01/13/itmn-intermune-fourth-quarter-esbriet-sales-snapshot/89940</link>
		<comments>http://www.stockbloghub.com/2012/01/13/itmn-intermune-fourth-quarter-esbriet-sales-snapshot/89940#comments</comments>
		<pubDate>Fri, 13 Jan 2012 20:59:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[InterMune Inc]]></category>
		<category><![CDATA[IPF]]></category>
		<category><![CDATA[ITMN]]></category>
		<category><![CDATA[NPP]]></category>
		<category><![CDATA[Nuveen Performance Plus Municipal Fund Inc]]></category>
		<category><![CDATA[SPDR S&P International Financial Sector]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89940</guid>
		<description><![CDATA[InterMune, Inc. (ITMN) recently reported preliminary fourth quarter revenue for its potential blockbuster drug Esbriet. Esbriet is approved in the European Union (EU) for the treatment of mild-to-moderate idiopathic pulmonary fibrosis (IPF). The drug has been launched first in Germany in September 2011. InterMune also announced updated data from the drug’s RECAP study. Preliminary Esbriet Update InterMune reported Esbriet revenue of $2.8 million since launch in September 2011, of which $2.7 million was generated in Germany. Management announced that 1,022 new patients started Esbriet therapy across EU at the end of 2011. Of these, 612 patients have been given Esbriet in Germany and 410 patients have enrolled in the named patient program (NPP) outside Germany. Under the NPP program qualified physicians can make Esbriet available to IPF patients in EU ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/13/itmn-intermune-fourth-quarter-esbriet-sales-snapshot/89940/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MCO) Fitch Has Eurozone Rating Misgivings</title>
		<link>http://www.stockbloghub.com/2011/12/20/mco-fitch-has-eurozone-rating-misgivings/88919</link>
		<comments>http://www.stockbloghub.com/2011/12/20/mco-fitch-has-eurozone-rating-misgivings/88919#comments</comments>
		<pubDate>Tue, 20 Dec 2011 18:13:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Credit Services]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[BK]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[MCO]]></category>
		<category><![CDATA[Moody's Corporation]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[The Bank of New York Mellon Corporation]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WFC]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88919</guid>
		<description><![CDATA[Ratings agency Fitch has misgivings about Europe’s ability to tackle the sovereign debt crisis. Moody’s, a division of Moody’s Corporation (MCO) and Standard &#38; Poor’s had earlier warned about the failing economic health of the European Union (EU) worsened by the indecision of the political class to address the crisis. At the recent summit, Europe tried to send positive signals to the market and the world about its sincerity to address the issue. Strong fiscal discipline, stronger economic coordination and the 500 billion euro fund to assist countries in crisis were among the significant measures that were announced. Europe has also agreed to lend 150 billion euros to IMF to shore up its resources. But the concern remains: will all this be enough? There are differences among countries. For example; ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/20/mco-fitch-has-eurozone-rating-misgivings/88919/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Dificlir Cleared in European Union</title>
		<link>http://www.stockbloghub.com/2011/12/15/optr-optimer-pharmaceuticals-dificlir-cleared-in-european-union/88596</link>
		<comments>http://www.stockbloghub.com/2011/12/15/optr-optimer-pharmaceuticals-dificlir-cleared-in-european-union/88596#comments</comments>
		<pubDate>Thu, 15 Dec 2011 10:00:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CDI]]></category>
		<category><![CDATA[CDI Corporation]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88596</guid>
		<description><![CDATA[Optimer Pharmaceuticals, Inc. (OPTR) and partner Astellas Pharma recently announced that their antibiotic Dificlir received approval in the European Union (EU), not belying expectations. The European Medicines Agency (EMA) cleared Dificlir for the treatment of clostridium difficile-associated diarrhea (CDAD) also known as clostridium difficile infection (CDI). CDAD is the most common nosocomial or hospital-acquired diarrhea and is a significant malaise in hospitals and nursing home facilities. The EU approval does not surprise us since in September this year Dificlir received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the EMA. Dificlir is already marketed as Dificid in the US for CDAD in partnership with Cubist Pharmaceuticals, Inc. (CBST). The European regulatory body’s decision was based on data from two late stage studies which showed ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/15/optr-optimer-pharmaceuticals-dificlir-cleared-in-european-union/88596/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MCO) Moody&#8217;s Follows with Eurozone Warning</title>
		<link>http://www.stockbloghub.com/2011/12/14/mco-moodys-follows-with-eurozone-warning/88546</link>
		<comments>http://www.stockbloghub.com/2011/12/14/mco-moodys-follows-with-eurozone-warning/88546#comments</comments>
		<pubDate>Wed, 14 Dec 2011 20:00:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Credit Services]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[BK]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[MCO]]></category>
		<category><![CDATA[Moody's Corporation]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[The Bank of New York Mellon Corporation]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WFC]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88546</guid>
		<description><![CDATA[Moody’s, a division of Moody’s Corporation (MCO), becomes the second ratings agency to sound a warning after Standard &#38; Poor’s on the failing economic health of the European Union (EU) partly fueled by the indecision of the political class to address the crisis. Although the markets were rattled by the announcement as most indices fell and Italian bond yields soared, the political leadership appears to have taken the downbeat mood in its stride. French President Nicolas Sarkozy said, it would be &#8220;one more difficulty, but not insurmountable&#8221; if France were to lose its AAA rating. At the recent summit, European leaders agreed on tougher fiscal discipline, such as balanced budgets on the part of individual countries and stronger economic coordination. However, the EU appears to be powerless without individual countries ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/14/mco-moodys-follows-with-eurozone-warning/88546/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Stock Market News for December 13, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/12/13/eu-stock-market-news-for-december-13-2011-market-news/88498</link>
		<comments>http://www.stockbloghub.com/2011/12/13/eu-stock-market-news-for-december-13-2011-market-news/88498#comments</comments>
		<pubDate>Tue, 13 Dec 2011 18:38:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Advanced Micro Devices Inc.]]></category>
		<category><![CDATA[AMD]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[BRCM]]></category>
		<category><![CDATA[Broadcom Corporation]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[ConocoPhillips]]></category>
		<category><![CDATA[COP]]></category>
		<category><![CDATA[DIS]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Financial Select Sector SPDR]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Hewlett-Packard Company]]></category>
		<category><![CDATA[HPQ]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[International Business Machines]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Marathon Oil Corporation]]></category>
		<category><![CDATA[MCD]]></category>
		<category><![CDATA[McDonald's Corporation]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MRO]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Occidental Petroleum Corporation]]></category>
		<category><![CDATA[OXY]]></category>
		<category><![CDATA[SU]]></category>
		<category><![CDATA[Suncor Energy Inc]]></category>
		<category><![CDATA[Texas Instruments Inc.]]></category>
		<category><![CDATA[TXN]]></category>
		<category><![CDATA[Walt Disney Company]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[XLF]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88498</guid>
		<description><![CDATA[Markets reversed gears on Monday and receded into negative territory after the European accord concluded on last Friday faced criticism from Fitch Ratings and Moody&#8217;s Investors Service. Tech-giant Intel also contributed to weak investor confidence after the company projected revenues lower than its earlier projections. The Dow Jones Industrial Average (DJIA) plunged 1.3% to close the day at 12,021.39. The Standard &#38; Poor 500 (S&#38;P 500) slumped 1.5% to finish the day’s trading at 1,236.47. The Nasdaq Composite Index settled substantively lower at 2,612.26, declining by 1.3%. However, the fear-gauge Volatility Index (VIX) showed that investor concerns had receded somewhat, dropping 2.7% to settle at 25.67. Decliners outpaced advancing stocks on the New York Stock Exchange (NYSE). For 77% of the decliners, merely 20% stocks managed to climb higher with ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/13/eu-stock-market-news-for-december-13-2011-market-news/88498/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Stock Market News for December 12, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/12/12/eu-stock-market-news-for-december-12-2011-market-news/88415</link>
		<comments>http://www.stockbloghub.com/2011/12/12/eu-stock-market-news-for-december-12-2011-market-news/88415#comments</comments>
		<pubDate>Mon, 12 Dec 2011 22:14:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Financial Select Sector SPDR]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WFC]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[XLF]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88415</guid>
		<description><![CDATA[Signs of a resolution to the lingering European debt crisis in the offing and a positive consumer data on the domestic front boosted the benchmarks on Friday. Thus, the markets elongated its weekly gains to the second-straight week and the S&#38;P 500 recorded its longest stretch of weekly gains since October. The Dow Jones Industrial Average (DJIA) gained 186 points or 1.6% to settle at 12,184.26. The Standard &#38; Poor 500 (S&#38;P 500) surged 1.7% and finished the day at 1,255.19. The Nasdaq Composite Index closed substantively higher at 2,646.85, after jumping 1.9%. While investors felt largely comfortable over the European developments, the fear-gauge CBOE Volatility Index (VIX) plunged almost 14% to close the day 26. 83. Thus, reflecting subdued fears in the markets, the fear-gauge index was comfortably below ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/12/eu-stock-market-news-for-december-12-2011-market-news/88415/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis&#8217; Cancer Drug Afinitor Shows Promise for Breast Cancer</title>
		<link>http://www.stockbloghub.com/2011/12/12/nvs-novartis-cancer-drug-afinitor-shows-promise-for-breast-cancer/88414</link>
		<comments>http://www.stockbloghub.com/2011/12/12/nvs-novartis-cancer-drug-afinitor-shows-promise-for-breast-cancer/88414#comments</comments>
		<pubDate>Mon, 12 Dec 2011 22:12:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PFS]]></category>
		<category><![CDATA[Provident Financial Services Inc]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88414</guid>
		<description><![CDATA[Novartis’ (NVS) cancer drug Afinitor took a significant step forward, as the company once again presented encouraging data from late-stage trials of Afinitor for the treatment of breast cancer, an indication for which management estimates sales potential in excess of $1 billion. Afinitor is not yet approved for the treatment of breast cancer. The pivotal late-stage study (BOLERO-2) evaluated the use of Afinitor in combination with Pfizer’s (PFE) Aromasin (a hormonal therapy) in postmenopausal women with metastatic breast cancer whose disease has progressed, despite treatment with hormonal therapies like Novartis’ Femara or AstraZeneca’s (AZN) Arimidex. The long-term data showed that Afinitor plus Aromasin expanded progression-free survival (PFS), or time, without causing tumor growth in patients, by more than two times versus Aromasin alone. Treatment with Afinitor improved the PFS to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/12/nvs-novartis-cancer-drug-afinitor-shows-promise-for-breast-cancer/88414/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Drug Cleared by the European Commission</title>
		<link>http://www.stockbloghub.com/2011/12/08/azn-astrazeneca-drug-cleared-by-the-european-commission/87920</link>
		<comments>http://www.stockbloghub.com/2011/12/08/azn-astrazeneca-drug-cleared-by-the-european-commission/87920#comments</comments>
		<pubDate>Thu, 08 Dec 2011 19:01:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87920</guid>
		<description><![CDATA[AstraZeneca (AZN) and its partner Bristol-Myers Squibb (BMY) announced recently that Komboglyze has been approved by the European Commission (EC) in European Union (EU). Komboglyze is a combination of Onglyza (saxagliptin), a DPP-4 inhibitor and metformin, a generic drug for type II diabetes. AstraZeneca has co-developed Onglyza with Bristol-Myers. The EC cleared Komboglyze as an adjunct to diet and exercise to improve glycemic control in adults suffering from type II diabetes. Komboglyze is indicated for patients who show inadequate response to the maximum tolerated dose of metformin alone or those already being treated with the combination of Onglyza and metformin as separate tablets. Komboglyze is expected to provide single pill dosing convenience to patients currently taking Onglyza and metformin seperately. We remind investors that Komboglyze was approved by the US ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/08/azn-astrazeneca-drug-cleared-by-the-european-commission/87920/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Emerging Markets: The Way Forward</title>
		<link>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206</link>
		<comments>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206#comments</comments>
		<pubDate>Wed, 07 Dec 2011 21:57:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88206</guid>
		<description><![CDATA[According to Irish orator, philosopher, &#38; politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well. Until recently, most commercialization efforts were focused on the U.S. &#8212; the largest pharmaceutical market &#8212; along with Europe and Japan. However, with factors like pricing pressure in the European Union (EU) and intensifying generic competition affecting sales in large pharmaceutical markets, many leading players in the pharmaceutical space such as Pfizer (PFE), Bristol &#8211; Myers Squibb Company (BMY), Merck (MRK), Eli Lilly (LLY), GlaxoSmithKline (GSK), Astra Zeneca (AZN) and Sanofi-Aventis (SNY), have shifted their focus on emerging (&#8220;pharmerging&#8221;) markets. The key emerging markets targeted by big players in the pharmaceutical space (aka “Big Pharma&#8221;) include China, Russia, Brazil, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WDC) Western Digital Clears Global Storage Technology Hurdle</title>
		<link>http://www.stockbloghub.com/2011/11/30/wdc-western-digital-clears-global-storage-technology-hurdle/87686</link>
		<comments>http://www.stockbloghub.com/2011/11/30/wdc-western-digital-clears-global-storage-technology-hurdle/87686#comments</comments>
		<pubDate>Wed, 30 Nov 2011 20:02:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Data Storage Devices]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HIT]]></category>
		<category><![CDATA[Hitachi Limited]]></category>
		<category><![CDATA[NOK]]></category>
		<category><![CDATA[Nokia Corporation]]></category>
		<category><![CDATA[Seagate Technology]]></category>
		<category><![CDATA[STX]]></category>
		<category><![CDATA[WDC]]></category>
		<category><![CDATA[Western Digital Corporation]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87686</guid>
		<description><![CDATA[Western Digital Corp. (WDC) is counting the days to wrap up the acquisition of Hitachi Ltd.’s (HIT) wholly owned subsidiary, Global Storage Technology (“HGST”). Last week, the top-tier hard disk drive (HDD) manufacturer received approval from the European Union (EU) that cleared all disputes regarding the takeover. In March 2011, Western Digital signed a definitive agreement to take over HGST, for approximately $4.3 billion. The acquisition was intended to make Western Digital a more customer-focused storage company, with significant operational scale and a product suite that would make it more competitive in the international market. On the other hand, some industry experts believe that the combined entity may lose some market share, as several smaller players are supplying HDDs at competitive prices. Regulators approved the deal only after Western Digital ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/30/wdc-western-digital-clears-global-storage-technology-hurdle/87686/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) ViroPharma Going Strong</title>
		<link>http://www.stockbloghub.com/2011/11/04/vphm-viropharma-going-strong/86191</link>
		<comments>http://www.stockbloghub.com/2011/11/04/vphm-viropharma-going-strong/86191#comments</comments>
		<pubDate>Fri, 04 Nov 2011 18:37:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86191</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) posted third quarter 2011 earnings (including special items) of 35 cents per share, surpassing the Zacks Consensus Estimate of 33 cents, but lower than the year-ago figure of 45 cents. Excluding special items, but including stock based compensation expense, earnings came in at 52 cents per share for the third quarter, reflecting an increase of 8.3%. Higher revenues and lower share count helped boost earnings. Revenues Higher sales from Cinryze helped improve quarterly revenues to $143.0 million, from $117.8 million reported in the year-ago quarter. Revenues also beat the Zacks Consensus Estimate of $131.0 million. Cinryze sales increased 33.2% to $65.4 million during the reported quarter, and Vancocin sales came in at $76.6 million, reflecting an increase of 13.3%. While the increase in Cinryze sales was due ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/04/vphm-viropharma-going-strong/86191/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Riding High on Incivek Sales</title>
		<link>http://www.stockbloghub.com/2011/11/02/vrtx-vertex-pharmaceuticals-riding-high-on-incivek-sales/86343</link>
		<comments>http://www.stockbloghub.com/2011/11/02/vrtx-vertex-pharmaceuticals-riding-high-on-incivek-sales/86343#comments</comments>
		<pubDate>Wed, 02 Nov 2011 17:08:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CF]]></category>
		<category><![CDATA[CF Industries Holdings Inc.]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86343</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) posted robust third quarter 2011 earnings (including stock-based compensation expense) of 56 cents per share, substantially above the Zacks Consensus Estimate of 19 cents and the year-ago loss of 99 cents. Increased revenues from the sale of hepatitis C virus (HCV) treatment, Incivek (telaprevir) helped record positive earnings. Revenues Riding on the strong sales of Incivek, which was launched in the second quarter of 2011, Vertex Pharma reported total revenue of $659.2 million, almost double the Zacks Consensus Estimate of $342 million and significantly above the year-ago figure of $23.8 million. Vertex Pharma’s third quarter revenues consisted of revenue earned from the sale of Incivek ($419.6 million), royalty revenue (up 4.5% to $8.5 million) and collaborative revenue (up 137.9% to $231.1 million). Collaborative revenue for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/02/vrtx-vertex-pharmaceuticals-riding-high-on-incivek-sales/86343/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Non-U.S. Banks Stock Update &#8211; November 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/11/01/eu-non-u-s-banks-stock-update-november-2011-industry-outlook/86280</link>
		<comments>http://www.stockbloghub.com/2011/11/01/eu-non-u-s-banks-stock-update-november-2011-industry-outlook/86280#comments</comments>
		<pubDate>Tue, 01 Nov 2011 18:08:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Banco Bradesco S.A.]]></category>
		<category><![CDATA[Banco de Chile]]></category>
		<category><![CDATA[Banco Latinoamericano de Exportaciones SA]]></category>
		<category><![CDATA[Banco Macro S.A.]]></category>
		<category><![CDATA[Banco Santander S.a.]]></category>
		<category><![CDATA[Banco Santander-Chile]]></category>
		<category><![CDATA[Bancolombia S.A.]]></category>
		<category><![CDATA[Bank of Montreal]]></category>
		<category><![CDATA[BAP]]></category>
		<category><![CDATA[Barclays plc]]></category>
		<category><![CDATA[BBD]]></category>
		<category><![CDATA[BBVA Banco Frances S.A.]]></category>
		<category><![CDATA[BCH]]></category>
		<category><![CDATA[BCS]]></category>
		<category><![CDATA[BFR]]></category>
		<category><![CDATA[BLX]]></category>
		<category><![CDATA[BMA]]></category>
		<category><![CDATA[BMO]]></category>
		<category><![CDATA[BNS]]></category>
		<category><![CDATA[Canadian Imperial Bank of Commerce]]></category>
		<category><![CDATA[CIB]]></category>
		<category><![CDATA[CM]]></category>
		<category><![CDATA[Credicorp Limited]]></category>
		<category><![CDATA[Credit Suisse Group]]></category>
		<category><![CDATA[CS]]></category>
		<category><![CDATA[DB]]></category>
		<category><![CDATA[Deutsche Bank AG]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[GGAL]]></category>
		<category><![CDATA[Grupo Financiero Galicia S.A.]]></category>
		<category><![CDATA[HBC]]></category>
		<category><![CDATA[HDB]]></category>
		<category><![CDATA[HDFC Bank Limited]]></category>
		<category><![CDATA[HSBC HLDGS PLC ADS]]></category>
		<category><![CDATA[IBN]]></category>
		<category><![CDATA[ICICI Bank Limited]]></category>
		<category><![CDATA[Itau Unibanco Holding Sa]]></category>
		<category><![CDATA[ITUB]]></category>
		<category><![CDATA[KB]]></category>
		<category><![CDATA[Kookmin Bank]]></category>
		<category><![CDATA[MFG]]></category>
		<category><![CDATA[Mitsubishi UFJ Financial Group Inc]]></category>
		<category><![CDATA[Mizuho Financial Group Inc.]]></category>
		<category><![CDATA[MTU]]></category>
		<category><![CDATA[National Bank of Greece SA]]></category>
		<category><![CDATA[NBG]]></category>
		<category><![CDATA[Royal Bank of Canada]]></category>
		<category><![CDATA[RY]]></category>
		<category><![CDATA[SAN]]></category>
		<category><![CDATA[Sauer-Danfoss Inc]]></category>
		<category><![CDATA[SHS]]></category>
		<category><![CDATA[STD]]></category>
		<category><![CDATA[TD]]></category>
		<category><![CDATA[The Bank Of Nova Scotia]]></category>
		<category><![CDATA[Toronto-Dominion Bank]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86280</guid>
		<description><![CDATA[The global banking industry is still a sorry sight, and its near term looks even worse with several negatives like asset-quality troubles, weak revenue growth, steeper costs and weak loan demand. But thanks to the worldwide regulatory reform, the sector has at least entered a transformation phase. Needless to mention, a change has yet to be felt. Potential threats from a deeper European debt crisis and the uncertain outlook for the U.S. economy following the rating downgrades by Standard &#38; Poor’s (S&#38;P) were quite obvious and the sector entered the second half of 2011 with a lot less momentum than was anticipated. Though the growth potential of some non-U.S. banks could be subdued due to higher reserve requirements, increased property taxes and strict lending limits as part of the regulatory ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/01/eu-non-u-s-banks-stock-update-november-2011-industry-outlook/86280/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Pharmaceuticals Stock Outlook &#8211; September 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930</link>
		<comments>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930#comments</comments>
		<pubDate>Fri, 23 Sep 2011 18:59:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ICAgen Inc]]></category>
		<category><![CDATA[ICGN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83930</guid>
		<description><![CDATA[The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance between new product launches and patent expirations. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Major revenue generating drugs like Lipitor, Plavix, Lexapro and Zyprexa are expected to confront generic competition over the next five years. In fact, revenues in excess of $30 billion are expected to be lost in 2011 itself due to key drugs like Lipitor and Zyprexa going off-patent. The impact of the genericization of these drugs will be felt significantly in 2012, which will be a challenging year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Drug Cleared in European Union for SEGA</title>
		<link>http://www.stockbloghub.com/2011/09/20/nvs-novartis-drug-cleared-in-eu-for-sega/83127</link>
		<comments>http://www.stockbloghub.com/2011/09/20/nvs-novartis-drug-cleared-in-eu-for-sega/83127#comments</comments>
		<pubDate>Tue, 20 Sep 2011 19:12:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83127</guid>
		<description><![CDATA[Novartis (NVS) recently received a boost when its drug Votubia was approved for the treatment of subependymal giant cell astrocytomas (SEGA), a benign brain tumor associated with tuberous sclerosis (TS) in the European Union (EU). For the first time ever will such a medication be available in this region for the treatment of this challenging disease. Votubia is already marketed in the US under the trade name Afinitor for the disease. It is also approved in Switzerland, Brazil, Colombia, Guatemala, the Philippines and South Korea to treat SEGA associated with TS. Earlier in June this year, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Votubia for the indication. The recommendation was based on data from a mid-stage study, which showed ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/nvs-novartis-drug-cleared-in-eu-for-sega/83127/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) Vivus&#8217; Erectile Dysfunction Drug Presents Positive Data</title>
		<link>http://www.stockbloghub.com/2011/09/20/vvus-vivus-erectile-dysfunction-drug-presents-positive-data/83159</link>
		<comments>http://www.stockbloghub.com/2011/09/20/vvus-vivus-erectile-dysfunction-drug-presents-positive-data/83159#comments</comments>
		<pubDate>Tue, 20 Sep 2011 18:50:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Consolidated Edison Inc.]]></category>
		<category><![CDATA[ED]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83159</guid>
		<description><![CDATA[Vivus Inc. (VVUS) recently presented positive data from a late-stage trial on its erectile dysfunction (ED) candidate, avanafil, at the 47th European Association for the Study of Diabetes Annual Meeting. The REVIEW-Diabetes study (TA-302), which enrolled 390 patients with type I and type II diabetes, demonstrated that patients receiving avanafil achieved significant improvement in erectile function. The data reported that patients dosed with avanafil showed improvement in the percentage of successful intercourse attempts, regardless of diabetes classification (type I or II), duration of diabetes, or baseline ED severity. Further, successful intercourse was achieved in some patients within 15 minutes of taking avanafil. Moreover, some patients experienced successful intercourse more than six hours after dosing. On average, the patients who enrolled for the study were 58 years old and had a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/vvus-vivus-erectile-dysfunction-drug-presents-positive-data/83159/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Chemical Industry Stock Outlook &#8211; September 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/09/16/eu-chemical-industry-stock-outlook-september-2011-industry-outlook/83472</link>
		<comments>http://www.stockbloghub.com/2011/09/16/eu-chemical-industry-stock-outlook-september-2011-industry-outlook/83472#comments</comments>
		<pubDate>Fri, 16 Sep 2011 22:47:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[ACC]]></category>
		<category><![CDATA[American Campus Communities Inc]]></category>
		<category><![CDATA[BAK]]></category>
		<category><![CDATA[Basf Se]]></category>
		<category><![CDATA[BASFY]]></category>
		<category><![CDATA[Braskem S.A.]]></category>
		<category><![CDATA[Calgon Carbon Corporation]]></category>
		<category><![CDATA[CCC]]></category>
		<category><![CDATA[CE]]></category>
		<category><![CDATA[Celanese Corporation]]></category>
		<category><![CDATA[DD]]></category>
		<category><![CDATA[DOW]]></category>
		<category><![CDATA[Eastman Chemical Company]]></category>
		<category><![CDATA[EI DuPont de Nemours & Company]]></category>
		<category><![CDATA[EMN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Mitsubishi UFJ Financial Group Inc]]></category>
		<category><![CDATA[MTU]]></category>
		<category><![CDATA[PPG]]></category>
		<category><![CDATA[PPG Industries Inc.]]></category>
		<category><![CDATA[The Dow Chemical Company]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83472</guid>
		<description><![CDATA[Chemicals are generally used to make a wide variety of consumer goods and are also used in agriculture, manufacturing, construction and service industries. The chemical industry itself consumes 26% of its own output. Major industrial customers include rubber and plastic products, textiles, apparel, petroleum refining, pulp and paper, and primary metals. The chemical industry has shown rapid growth for more than fifty years. The fastest-growing areas have involved the manufacture of synthetic organic polymers used as plastics, fibers and elastomers. Globally, the chemical industry is mainly concentrated in three areas of the world: Western Europe, North America and Japan. The European community is the largest producer, followed by the U.S. and Japan. Chemicals are a nearly $3 trillion global business, and the European Union (EU) and U.S. chemical companies are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/16/eu-chemical-industry-stock-outlook-september-2011-industry-outlook/83472/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca&#8217;s Brilinta Now in US</title>
		<link>http://www.stockbloghub.com/2011/09/15/azn-astrazenecas-brilinta-now-in-us/81949</link>
		<comments>http://www.stockbloghub.com/2011/09/15/azn-astrazenecas-brilinta-now-in-us/81949#comments</comments>
		<pubDate>Thu, 15 Sep 2011 17:47:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81949</guid>
		<description><![CDATA[AstraZeneca plc (AZN) recently announced the US launch of Brilinta (ticagrelor). The drug was approved by the US Food and Drug Administration (FDA) last month, to reduce the rate of heart attack and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS). Following the launch, AstraZeneca plans to work with distribution partners and pharmacy customers to ensure that Brilinta is readily available for use. The regulatory body’s approval was based on the PLATO study, which compared Brilinta to clopidogrel in 18,624 patients suffering from ACS. The study demonstrated that there was no statistical difference in adverse reactions observed among patients treated with Brilinta, compared to those treated with clopidogrel. Clopidogrel, which is marketed worldwide by Bristol-Myers Squibb &#38; Co. (BMY) and Sanofi-Aventis (SNY) under the brand name Plavix, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/15/azn-astrazenecas-brilinta-now-in-us/81949/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Reports Positive Data</title>
		<link>http://www.stockbloghub.com/2011/09/12/vrtx-vertex-pharmaceuticals-reports-positive-data/82979</link>
		<comments>http://www.stockbloghub.com/2011/09/12/vrtx-vertex-pharmaceuticals-reports-positive-data/82979#comments</comments>
		<pubDate>Mon, 12 Sep 2011 17:19:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BID]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[Railamerica Inc]]></category>
		<category><![CDATA[Sotheby's]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82979</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) reported positive data from a mid-stage trial on VX-509, which is being studied for the treatment of moderate to severe rheumatoid arthritis (RA). The 12-week study, which evaluated four doses of the candidate, met both the primary endpoints. Data from the two highest dose (100 mg and 150 mg) treatment arms demonstrated significant improvement in the proportion of people who achieved at least a 20% improvement in the signs and symptoms of RA (ACR20), and a statistically significant improvement from baseline in Disease Activity Score 28 (DAS28), compared to placebo. The study also met the secondary endpoints (ACR50 and ACR70) of achieving statistically significant responses compared to placebo. On the basis of the data from the phase IIa study, Vertex Pharma plans to initiate a six-month ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/12/vrtx-vertex-pharmaceuticals-reports-positive-data/82979/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Neuroendocrine Tumors Drug Cleared in European Union</title>
		<link>http://www.stockbloghub.com/2011/09/11/nvs-novartis-neuroendocrine-tumors-drug-cleared-in-european-union/82655</link>
		<comments>http://www.stockbloghub.com/2011/09/11/nvs-novartis-neuroendocrine-tumors-drug-cleared-in-european-union/82655#comments</comments>
		<pubDate>Sun, 11 Sep 2011 19:54:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Arlington Asset Investment Corporation]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Stephan Company]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[TSC]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82655</guid>
		<description><![CDATA[Novartis’(NVS) drug Afinitor was recently approved in the European Union (EU) for the treatment of patients with advanced neuroendocrine tumors (NET) of pancreatic origin with progressive disease. The drug is already approved in the US for the indication. The approval was based on the RADIANT-3 trial which demonstrated that Afinitor led to a statistically significant improvement in progression-free survival versus placebo. The number of months of survival without the disease progressing was 11 months for a patient treated with Afinitor versus 4.6 months for a patient on placebo. Afinitor is currently marketed for the treatment of advanced renal cell carcinoma (kidney cancer) after an anti-VEGF therapy like Roche’s (RHHBY) Avastin, Pfizer’s (PFE) Sutent or Onyx Pharmaceuticals’(ONXX) Nexavar in the US and EU. In June this year, the Committee for Medicinal ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/11/nvs-novartis-neuroendocrine-tumors-drug-cleared-in-european-union/82655/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/09/01/alks-alkermes-analyst-maintains-neutral-rating-on-shares/82387</link>
		<comments>http://www.stockbloghub.com/2011/09/01/alks-alkermes-analyst-maintains-neutral-rating-on-shares/82387#comments</comments>
		<pubDate>Thu, 01 Sep 2011 16:55:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82387</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS). Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system (CNS) disorders, alcoholism and diabetes. In August 2011, Alkermes disclosed financial results for the first quarter of fiscal 2012. Alkermes suffered a net loss (excluding special items but including stock-based compensation expense) of $0.04 per share which compared favorably with the year-ago loss of $0.14 per share. The Zacks Consensus Estimate was a loss of $0.11 per share. The narrower year-over-year loss was attributable to higher revenues recorded in the reported quarter. The lead product at Alkermes is Risperdal Consta for the treatment of schizophrenia and bipolar disorder. The drug is marketed worldwide by Johnson ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/01/alks-alkermes-analyst-maintains-neutral-rating-on-shares/82387/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Analyst Maintains Outperform on Shares</title>
		<link>http://www.stockbloghub.com/2011/08/26/wpi-watson-pharmaceuticals-analyst-maintains-outperform-on-shares/82145</link>
		<comments>http://www.stockbloghub.com/2011/08/26/wpi-watson-pharmaceuticals-analyst-maintains-outperform-on-shares/82145#comments</comments>
		<pubDate>Fri, 26 Aug 2011 22:26:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WCRX]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82145</guid>
		<description><![CDATA[We continue to have an Outperform recommendation on Watson Pharmaceuticals, Inc. (WPI), with a target price of $79.00, following the release of second quarter 2011 results. Watson Pharma’s second quarter earnings of $1.01 per share (excluding special items) outpaced the Zacks Consensus Estimate by a penny and the year-ago earnings by 18 cents. Earnings were bolstered by higher revenues. Revenues for the quarter climbed 24% to $1.08 billion, beating the Zacks Consensus Estimate of $992 million. Revenues went up mainly due to increased generic and branded drug sales. Following the better-than-expected second quarter results, Watson Pharma increased its 2011 earning guidance range to $4.25-$4.50 per share from $3.95-$4.20. We note that the company enjoys a strong position in the generic pharmaceutical market. At the end of 2010, Watson Pharma had ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/26/wpi-watson-pharmaceuticals-analyst-maintains-outperform-on-shares/82145/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Analyst Maintains Neutral Recommendation</title>
		<link>http://www.stockbloghub.com/2011/08/22/hgsi-human-genome-sciences-analyst-maintains-neutral-recommendation/81747</link>
		<comments>http://www.stockbloghub.com/2011/08/22/hgsi-human-genome-sciences-analyst-maintains-neutral-recommendation/81747#comments</comments>
		<pubDate>Mon, 22 Aug 2011 14:47:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sara Lee Corporation]]></category>
		<category><![CDATA[SLE]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81747</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Human Genome Sciences Inc. (HGSI) with a target price of $16.00. Human Genome, founded in 1992 and based in Rockville, Maryland, is a biopharmaceutical company. The US launch of Benlysta earlier in the year for treating patients suffering from systemic lupus erythematosus (SLE) is a huge positive for Human Genome. The subsequent approvals of the drug in the European Union (EU) and Canada are also encouraging. The drug, which has blockbuster potential, has been co-developed with GlaxoSmithKline (GSK). Benlysta is the first new lupus drug to be cleared in more than 50 years. Lupus is a potentially fatal autoimmune disease that is extremely difficult to treat. We believe that the approval of this potentially blockbuster candidate will drive Human Genome to profitability. Benlysta ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/22/hgsi-human-genome-sciences-analyst-maintains-neutral-recommendation/81747/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Stock Market News for August 17, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/08/18/eu-stock-market-news-for-august-17-2011-market-news/81507</link>
		<comments>http://www.stockbloghub.com/2011/08/18/eu-stock-market-news-for-august-17-2011-market-news/81507#comments</comments>
		<pubDate>Fri, 19 Aug 2011 00:48:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[UBS]]></category>
		<category><![CDATA[UBS AG]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81507</guid>
		<description><![CDATA[Concerns from European corner once again pulled down the markets, as reports about a slowdown in the German economy led to the benchmarks’ first fall in four days. Failed talks between the French and German heads over a resolution to euro-zone debt woes overshadowed positive corporate results and Fitch’s decision to retain the US’ AAA rating. On yet another volatile trading day, the Dow Jones Industrial Average (DJIA) lost 76 points or 0.7% to finish the day at 11,405.93. For the first time in seven trading days, the blue-chip index moved by less than 100 points.The Standard &#38; Poor 500 (S&#38;P 500) dropped 1% to settle at 1,192.76. The Nasdaq Composite index declined by 1.2% and closed the day at 2,523.45. On the New York Stock Exchange (NYSE) consolidated volumes ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/18/eu-stock-market-news-for-august-17-2011-market-news/81507/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACOR) Acorda Therapeutics Gains &#8211; Earnings Miss Estimates</title>
		<link>http://www.stockbloghub.com/2011/08/04/acor-acorda-therapeutics-gains-earnings-miss-estimates/80628</link>
		<comments>http://www.stockbloghub.com/2011/08/04/acor-acorda-therapeutics-gains-earnings-miss-estimates/80628#comments</comments>
		<pubDate>Thu, 04 Aug 2011 15:47:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80628</guid>
		<description><![CDATA[Acorda Therapeutics Inc. (ACOR) recorded adjusted earnings of 7 cents per share for the second quarter of fiscal 2011, compared with a loss of 18 cents in the year-ago period. The Zacks Consensus Earnings Estimate for the quarter was 12 cents per share. Higher revenues during the quarter led to the surge in the company’s earnings. Revenues Quarterly revenues shot up 52.4% to $65.3 million, driven primarily by strong Ampyra sales. However, revenues marginally missed the Zacks Consensus Estimate of $67 million. Second quarter revenues comprised $62.9 million (up 55.3%) in product sales and $2.4 million (flat year over year) in license and royalty revenue. Sales of Ampyra, which was launched in March 2010, came in at $51.8 million, reflecting a year-over-year increase of 85%. Ampyra, aimed at improving walking ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/04/acor-acorda-therapeutics-gains-earnings-miss-estimates/80628/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AGN) Allergan Beats &#8211; Revisits Guidance</title>
		<link>http://www.stockbloghub.com/2011/08/03/agn-allergan-beats-revisits-guidance/80566</link>
		<comments>http://www.stockbloghub.com/2011/08/03/agn-allergan-beats-revisits-guidance/80566#comments</comments>
		<pubDate>Wed, 03 Aug 2011 23:12:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MAP Pharmaceuticals Inc]]></category>
		<category><![CDATA[MAPP]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[MRX]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80566</guid>
		<description><![CDATA[Allergan, Inc.’s (AGN) second quarter 2011 earnings of 96 cents per share inched ahead of the Zacks Consensus Estimate by a penny and surpassed the company’s guidance range of 93 – 95 cents. Earnings increased 12.9% from the year-ago quarter. Revenues Revenues increased 13.6% to $1,417.2 million, easily exceeding the Zacks Consensus Estimate of $1,339 million. Specialty pharmaceuticals sales increased 14.0% to $1,155.3 million, with eye care pharmaceutical sales increasing 13.8%. Strong performance of products like Lumigan and Restasis helped drive eye-care sales. Alphagan and Combigan franchise sales went up 4.1% to $108.5 million in the reported quarter. New product Latisse contributed $21.9 million to the second quarter sales. Botox sales increased 16.1% year on year to $418.4 million. Going forward, Allergan is looking to boost Botox sales by gaining ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/03/agn-allergan-beats-revisits-guidance/80566/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Quarterly Earnings Lag &#8211; Company Pares Loss</title>
		<link>http://www.stockbloghub.com/2011/08/03/ctic-cell-therapeutics-quarterly-earnings-lag-company-pares-loss/80335</link>
		<comments>http://www.stockbloghub.com/2011/08/03/ctic-cell-therapeutics-quarterly-earnings-lag-company-pares-loss/80335#comments</comments>
		<pubDate>Wed, 03 Aug 2011 15:45:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[MDS]]></category>
		<category><![CDATA[Midas Inc.]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80335</guid>
		<description><![CDATA[Cell Therapeutics (CTIC) suffered a net loss of 14 cents per share in the second quarter of 2011, compared with a net loss of 46 cents (excluding special items) per share in the year-ago quarter. The narrower loss per share in the reported quarter was due to lower operating expenses and lower deemed dividend paid to preferred shareholders. The Zacks Consensus Estimate for the reported quarter was a loss of 12 cents per share. Cell Therapeutics did not generate any revenue during the reported quarter versus $0.029 million in the second quarter of 2010. Total operating expense in the quarter declined 15% to $16.9 million. Pipeline Update In June this year, Cell Therapeutics met with the Division of Oncology Drug Products (the DODP) of the US Food and Drug Administration ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/03/ctic-cell-therapeutics-quarterly-earnings-lag-company-pares-loss/80335/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) ViroPharma Quarterly Earnings Report Misses Due to Higher Expenses</title>
		<link>http://www.stockbloghub.com/2011/08/03/vphm-viropharma-quarterly-earnings-report-misses-due-to-higher-expenses/80406</link>
		<comments>http://www.stockbloghub.com/2011/08/03/vphm-viropharma-quarterly-earnings-report-misses-due-to-higher-expenses/80406#comments</comments>
		<pubDate>Wed, 03 Aug 2011 15:34:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80406</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) posted second quarter fiscal 2011 earnings of 36 cents per share, missing the Zacks Consensus Estimate by 3 cents and the year-ago figure by a penny. Despite higher revenues, earnings bore the brunt of increased operating expenses. Revenues Higher sales from Cinryze boosted the quarterly revenues from $109.0 million in the year-ago quarter to $128.8 million. However, revenues fell shy of the Zacks Consensus Estimate of $131.0 million. Cinryze sales increased 55.1% to $62.5 million during the reported quarter, while Vancocin sales came in at $65.2 million, reflecting a slide of 4.7%. The increase in Cinryze sales was due to higher patient demand. On the other hand, Vancocin sales were negatively impacted by declining volume, partly offset by price rise. Other Details Research and development (R&#38;D) expenses ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/03/vphm-viropharma-quarterly-earnings-report-misses-due-to-higher-expenses/80406/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Loss Reduced by Incivek</title>
		<link>http://www.stockbloghub.com/2011/08/01/vrtx-vertex-pharmaceuticals-loss-reduced-by-incivek/80310</link>
		<comments>http://www.stockbloghub.com/2011/08/01/vrtx-vertex-pharmaceuticals-loss-reduced-by-incivek/80310#comments</comments>
		<pubDate>Mon, 01 Aug 2011 16:40:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CF]]></category>
		<category><![CDATA[CF Industries Holdings Inc.]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80310</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) posted second quarter 2011 loss (including stock-based compensation expense) of 82 cents per share, narrower than the Zacks Consensus Estimate of 93 cents and the year-ago loss of 83 cents. Increased revenues from the sale of hepatitis C virus (HCV) candidate, Incivek (telaprevir) helped reduce the loss. Revenues Riding on the strong sales of Incivek, which was launched during the quarter, total revenue soared 262% to $114.4 million, surpassing the Zacks Consensus Estimate of $54 million. Vertex Pharma’s first quarter revenues consisted of revenue earned from the sale of Incivek ($74.5 million), royalty revenue (up 37.8% to $10.0 million) and collaborative revenue (up 22.7% to $30.0 million). The company receives royalty from GlaxoSmithKline plc (GSK) on sales of Lexiva, a HIV protease inhibitor. Collaborative revenue consists ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/01/vrtx-vertex-pharmaceuticals-loss-reduced-by-incivek/80310/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis AG&#8217;s Afinitor Impresses Again</title>
		<link>http://www.stockbloghub.com/2011/07/07/nvs-novartis-ags-afinitor-impresses-again/78554</link>
		<comments>http://www.stockbloghub.com/2011/07/07/nvs-novartis-ags-afinitor-impresses-again/78554#comments</comments>
		<pubDate>Thu, 07 Jul 2011 17:02:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PFS]]></category>
		<category><![CDATA[Provident Financial Services Inc]]></category>
		<category><![CDATA[Stephan Company]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[TSC]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78554</guid>
		<description><![CDATA[It seems Novartis AG’s (NVS) breast cancer drug, Afinitor (everolimus), is getting into a habit of delivering positive news. Right after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Afinitor last week for the treatment of subependymal giant cell astrocytomas (SEGA), the drug impressed again this week with positive interim results from a pivotal late-stage trial (BOLERO-2). BOLERO-2 evaluated Afinitor in combination with exemestane versus placebo plus exemestane in postmenopausal women with estrogen receptor-positive locally-advanced breast cancer, whose disease progressed, despite treatment with the nonsteroidal aromatase inhibitors letrozole or anastrozole. The trial results demonstrated that patients with advanced breast cancer who were dosed Afinitor in combination with exemestane, experienced significantly extended progression-free survival (PFS), as compared to patients who received ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/07/nvs-novartis-ags-afinitor-impresses-again/78554/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(UBS) Non-U.S. Banks Stock Update &#8211; July 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/07/06/ubs-non-u-s-banks-stock-update-july-2011-industry-outlook/78469</link>
		<comments>http://www.stockbloghub.com/2011/07/06/ubs-non-u-s-banks-stock-update-july-2011-industry-outlook/78469#comments</comments>
		<pubDate>Wed, 06 Jul 2011 19:32:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Foreign Money Center Banks]]></category>
		<category><![CDATA[Banco Bradesco S.A.]]></category>
		<category><![CDATA[Banco de Chile]]></category>
		<category><![CDATA[Banco Santander S.a.]]></category>
		<category><![CDATA[Banco Santander-Chile]]></category>
		<category><![CDATA[Bank of Montreal]]></category>
		<category><![CDATA[Barclays plc]]></category>
		<category><![CDATA[BBD]]></category>
		<category><![CDATA[BCH]]></category>
		<category><![CDATA[BCS]]></category>
		<category><![CDATA[BMO]]></category>
		<category><![CDATA[BNS]]></category>
		<category><![CDATA[Canadian Imperial Bank of Commerce]]></category>
		<category><![CDATA[CM]]></category>
		<category><![CDATA[Credit Suisse Group]]></category>
		<category><![CDATA[CS]]></category>
		<category><![CDATA[DB]]></category>
		<category><![CDATA[Deutsche Bank AG]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[GGAL]]></category>
		<category><![CDATA[Grupo Financiero Galicia S.A.]]></category>
		<category><![CDATA[HBC]]></category>
		<category><![CDATA[HDB]]></category>
		<category><![CDATA[HDFC Bank Limited]]></category>
		<category><![CDATA[HSBC HLDGS PLC ADS]]></category>
		<category><![CDATA[IBN]]></category>
		<category><![CDATA[ICICI Bank Limited]]></category>
		<category><![CDATA[Itau Unibanco Holding Sa]]></category>
		<category><![CDATA[ITUB]]></category>
		<category><![CDATA[KB]]></category>
		<category><![CDATA[Kookmin Bank]]></category>
		<category><![CDATA[Lloyds Banking Group plc]]></category>
		<category><![CDATA[LYG]]></category>
		<category><![CDATA[National Bank of Greece SA]]></category>
		<category><![CDATA[NBG]]></category>
		<category><![CDATA[Royal Bank of Canada]]></category>
		<category><![CDATA[RY]]></category>
		<category><![CDATA[SAN]]></category>
		<category><![CDATA[SHG]]></category>
		<category><![CDATA[Shinhan Financial Group Company Limited]]></category>
		<category><![CDATA[STD]]></category>
		<category><![CDATA[TD]]></category>
		<category><![CDATA[The Bank Of Nova Scotia]]></category>
		<category><![CDATA[Toronto-Dominion Bank]]></category>
		<category><![CDATA[UBS]]></category>
		<category><![CDATA[UBS AG]]></category>
		<category><![CDATA[WBK]]></category>
		<category><![CDATA[Westpac Banking Corporation]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78469</guid>
		<description><![CDATA[Backed by worldwide regulatory reform, the global banking industry is currently going through a transformation phase. Though the growth potential of some non-U.S. banks could be subdued due to higher reserve requirements, increased property taxes and strict lending limits as part of the regulatory overhaul, greater transparency in regulation could strengthen the fundamentals of many banks. Moreover, it is expected to create a less risky lane for the overall industry. Since 2010, the banking sector has been recovering at a moderate pace from the latest financial crisis that started as a credit issue in the subprime enclave of the U.S. mortgage market in mid-2007 and spilled all over the globe. Though the malice spread by the financial crisis is behind us, banks are now dealing with regulatory pressure as they ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/06/ubs-non-u-s-banks-stock-update-july-2011-industry-outlook/78469/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALXN) Alexion Pharmaceuticals Stands at Neutral</title>
		<link>http://www.stockbloghub.com/2011/07/06/alxn-alexion-pharmaceuticals-stands-at-neutral/78471</link>
		<comments>http://www.stockbloghub.com/2011/07/06/alxn-alexion-pharmaceuticals-stands-at-neutral/78471#comments</comments>
		<pubDate>Wed, 06 Jul 2011 19:32:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AHR]]></category>
		<category><![CDATA[Alexion Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALXN]]></category>
		<category><![CDATA[Anthracite Capital Inc.]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78471</guid>
		<description><![CDATA[We are maintaining our Neutral stance on Alexion Pharmaceuticals (ALXN) with a target price of $49.00. Alexion Pharma delivered a strong performance in the first quarter of 2011. First quarter earnings (excluding special items but including stock-based compensation) of 23 cents per share surpassed the Zacks Consensus Estimate by 2 cents and the year-ago earnings by 12 cents. Earnings include the effect of the two-for-one stock split which was completed in May 2011. Earnings in the quarter benefited from an increase in revenues. The main growth driver at Alexion Pharma is Soliris, which is marketed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare genetic blood disorder. We note that strong Soliris sales have bolstered the company&#8217;s profitability since the second quarter of 2008. Besides PNH, Alexion Pharma is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/06/alxn-alexion-pharmaceuticals-stands-at-neutral/78471/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMD) Roche Holdings Gets Positive Data on Lucentis</title>
		<link>http://www.stockbloghub.com/2011/06/29/amd-roche-holdings-gets-positive-data-on-lucentis/77892</link>
		<comments>http://www.stockbloghub.com/2011/06/29/amd-roche-holdings-gets-positive-data-on-lucentis/77892#comments</comments>
		<pubDate>Wed, 29 Jun 2011 21:00:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Semiconductor - Broad Line]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Advanced Micro Devices Inc.]]></category>
		<category><![CDATA[AMD]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77892</guid>
		<description><![CDATA[Roche Holdings Ltd. (RHHBY) recently reported positive data from two late-stage studies (RISE and RIDE) on its eye drug, Lucentis. The studies were conducted to evaluate the safety and efficacy of the drug in patients suffering from diabetic macular edema (DME). DME leads to swelling of the retina in patients with type I or type II diabetes. The disease can cause blurred vision, severe vision loss and at times blindness. Data from the trials demonstrated that the patients, after 24 months of treatment with Lucentis, experienced significant, rapid and sustained improvement in vision compared to those who were given placebo. Roche also confirmed that patients experienced an improvement in vision within seven days of starting treatment with Lucentis. The company added that patients on Lucentis also experienced decreased retinal swelling. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/amd-roche-holdings-gets-positive-data-on-lucentis/77892/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb and Pfizer Report Positive Data on Blood Thinner Apixaban Drug</title>
		<link>http://www.stockbloghub.com/2011/06/24/bmy-bristol-myers-squibb-and-pfizer-report-positive-data-on-blood-thinner-apixaban-drug/77318</link>
		<comments>http://www.stockbloghub.com/2011/06/24/bmy-bristol-myers-squibb-and-pfizer-report-positive-data-on-blood-thinner-apixaban-drug/77318#comments</comments>
		<pubDate>Fri, 24 Jun 2011 16:18:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[Astoria Financial Corporation]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77318</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer (PFE) announced encouraging top line data from a late-stage study (ARISTOTLE: n=18,201) which evaluated their blood thinner apixaban in patients suffering from an erratic heartbeat. This cardiac rhythm disorder is referred to as atrial fibrillation (AF). Apixaban will be marketed under the trade name Eliquis in the EU. The same trade name has been proposed in the US and other countries. Top-line results from the double-blind, multicenter study revealed that Eliquis was non-inferior to the standard therapy warfarin with respect to the combined outcome of stroke and systemic embolism. Data further revealed that Eliquis was superior to warfarin with respect to effectiveness and major bleeding. Bristol-Myers and Pfizer intend to seek approval from the US Food and Drug Administration (FDA) and also ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/bmy-bristol-myers-squibb-and-pfizer-report-positive-data-on-blood-thinner-apixaban-drug/77318/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec and Partner Elan Announce EU Label Update for Tysabri</title>
		<link>http://www.stockbloghub.com/2011/06/22/biib-biogen-idec-and-partner-elan-announce-eu-label-update-for-tysabri/77127</link>
		<comments>http://www.stockbloghub.com/2011/06/22/biib-biogen-idec-and-partner-elan-announce-eu-label-update-for-tysabri/77127#comments</comments>
		<pubDate>Wed, 22 Jun 2011 19:16:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PIMCO Municipal Income Fund II]]></category>
		<category><![CDATA[PML]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77127</guid>
		<description><![CDATA[Recently, Biogen Idec, Inc. (BIIB) and partner Elan Corporation (ELN) announced that the European Commission (EC) has approved an update to the label for their multiple sclerosis (MS) drug Tysabri (natalizumab) in the European Union (EU). The updated label includes anti-JC Virus antibody status as an additional factor that could help stratify the risk of progressive multifocal leukoencephalopathy (PML) occurring in patients treated with Tysabri. The EC’s decision for the label update does not surprise us as in April 2011 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) had backed the inclusion of the additional risk in the Tysabri label. The updated label in the EU will provide patients (treated with Tysabri) as well as doctors additional assistance in identifying the risk of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/biib-biogen-idec-and-partner-elan-announce-eu-label-update-for-tysabri/77127/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) Vivus&#8217; Erectile Dysfunction Drug on Track</title>
		<link>http://www.stockbloghub.com/2011/06/22/vvus-vivus-erectile-dysfunction-drug-on-track/77061</link>
		<comments>http://www.stockbloghub.com/2011/06/22/vvus-vivus-erectile-dysfunction-drug-on-track/77061#comments</comments>
		<pubDate>Wed, 22 Jun 2011 17:02:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Consolidated Edison Inc.]]></category>
		<category><![CDATA[ED]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77061</guid>
		<description><![CDATA[Vivus Inc. (VVUS) recently reported positive results from a late-stage trial, REVIVE-RP (TA-303), on avanafil. The study evaluated the safety and efficacy of avanafil in the treatment of erectile dysfunction (ED) following bilateral, nerve-sparing, radical prostatectomy. The candidate met all the primary endpoints of the study, which included improvement from baseline in erectile function as measured by the Sexual Encounter Profile (both SEP2 and SEP3) and improvement in the International Index of Erectile Function (IIEF). Additionally, the data showed that successful intercourse was achieved within 15 minutes of taking avanafil. On average, the patients who enrolled for the study were 58 years old, 19 months past their prostatectomy surgery dates and diagnosed with severe ED. The patients were given 100 mg or 200 mg of avanafil or placebo and were ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/vvus-vivus-erectile-dysfunction-drug-on-track/77061/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(REGN) Regeneron Pharmaceuticals Wins Unanious FDA Panel Approval</title>
		<link>http://www.stockbloghub.com/2011/06/21/regn-regeneron-pharmaceuticals-wins-unanious-fda-panel-approval/76846</link>
		<comments>http://www.stockbloghub.com/2011/06/21/regn-regeneron-pharmaceuticals-wins-unanious-fda-panel-approval/76846#comments</comments>
		<pubDate>Tue, 21 Jun 2011 19:00:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Regeneron Pharmaceuticals Inc]]></category>
		<category><![CDATA[REGN]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76846</guid>
		<description><![CDATA[Recently, the Dermatologic and Ophthalmic Advisory Committee of the US Food and Drug Administration (FDA) issued a positive opinion and unanimously recommended the US approval of Regeneron Pharmaceuticals Inc.’s (REGN) eye treatment VEGF (vascular endothelial growth factor) trap-eye (proposed trade name: Eylea). The panel recommended the clearance of the candidate in the US for treating patients suffering from the neovascular form of age-related macular degeneration (wet AMD). A decision from the FDA is expected by August 20, 2011 (target date). Although the FDA is not bound to accept the recommendation of the advisory committee, it usually does so. We remind investors that Regeneron submitted a biologics license application (BLA) to the FDA seeking marketing approval of the drug for the wet AMD indication in February 2011. The BLA was based ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/21/regn-regeneron-pharmaceuticals-wins-unanious-fda-panel-approval/76846/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) UCB Reports Data on Neupro</title>
		<link>http://www.stockbloghub.com/2011/06/19/eu-ucb-reports-data-on-neupro/76677</link>
		<comments>http://www.stockbloghub.com/2011/06/19/eu-ucb-reports-data-on-neupro/76677#comments</comments>
		<pubDate>Sun, 19 Jun 2011 17:34:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76677</guid>
		<description><![CDATA[UCB (UCBJF) recently reported results from post hoc analyses of its restless legs syndrome (RLS) treatment Neupro (rotigotine). The data were presented at the International Congress of Parkinson’s disease and Movement disorders. RLS is a neurological disorder that causes an uncontrollable urge to move the legs during periods of inactivity or rest. This disorder mainly occurs late in the evening and at night. However, epidemiological studies and UCB’s post hoc analysis suggested that patients may experience symptoms during the daytime also, leading to impairment of daytime functioning. The results from the post hoc analyses, which analyzed a six month study on Neupro in 458 patients, suggested patients dosed with Neupro (1 mg, 2 mg and 3 mg per 24 hours) experienced an improvement in daytime functioning and daytime symptoms compared ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/19/eu-ucb-reports-data-on-neupro/76677/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(COF) Capital One Acquires ING Direct USA</title>
		<link>http://www.stockbloghub.com/2011/06/19/cof-capital-one-acquires-ing-direct-usa/76708</link>
		<comments>http://www.stockbloghub.com/2011/06/19/cof-capital-one-acquires-ing-direct-usa/76708#comments</comments>
		<pubDate>Sun, 19 Jun 2011 17:26:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Credit Services]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Capital One Financial Corporation]]></category>
		<category><![CDATA[CIT]]></category>
		<category><![CDATA[CIT Group Inc.]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[COF]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[ING]]></category>
		<category><![CDATA[ING Groep NV]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76708</guid>
		<description><![CDATA[Capital One Financial Corp.(COF) announced an agreement to acquire ING Direct USA, the online banking unit of Amsterdam-based ING Groep NV (ING), in a stock-cum-cash transaction valued at $9.0 billion. The deal would catapult the company to fifth position from the present eighth, in terms of deposits in the U.S. Earlier this month, Capital One and General Electric Co. (GE) had submitted their bids to acquire ING Direct USA. Other companies that had shown interest in acquiring ING Direct USA, were CIT Group Inc. (CIT), SJB National Bank, Ally Financial Inc. and Citigroup Inc. (C). According to the condition with the European Union (EU) to get government bailout during the financial crisis, ING Groep is selling its U.S. unit. However, this deal would not affect ING Direct’s operations in Canada, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/19/cof-capital-one-acquires-ing-direct-usa/76708/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Company Gets Another Feather in its Cap</title>
		<link>http://www.stockbloghub.com/2011/06/17/bmy-bristol-myers-squibb-company-gets-another-feather-in-its-cap/76633</link>
		<comments>http://www.stockbloghub.com/2011/06/17/bmy-bristol-myers-squibb-company-gets-another-feather-in-its-cap/76633#comments</comments>
		<pubDate>Fri, 17 Jun 2011 14:42:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76633</guid>
		<description><![CDATA[Bristol-Myers Squibb Company’s (BMY) product portfolio was boosted further when the US Food and Drug Administration (FDA) approved its drug Nulojix (belatacept) to prevent the rejection of transplanted kidneys in adults. We remind investors that Bristol-Myers has succeeded in getting the drug approved in the US for the indication in its second attempt. In the second quarter of 2010, the FDA issued a complete response letter in response to biologic license application (BLA) submitted by the pharma major for Nulojix , asking for additional information. Subsequently, Bristol-Myers submitted it. In December 2010, the agency had thereby announced that it would review the re-submitted application by June 15, 2011 (action date). The agency cleared the drug following the review thereby delivering a further boost to the company. We note that the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/17/bmy-bristol-myers-squibb-company-gets-another-feather-in-its-cap/76633/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACOR) Acorda Therapeutics Gets Mixed Data on Ampyra</title>
		<link>http://www.stockbloghub.com/2011/06/16/acor-acorda-therapeutics-gets-mixed-data-on-ampyra/76214</link>
		<comments>http://www.stockbloghub.com/2011/06/16/acor-acorda-therapeutics-gets-mixed-data-on-ampyra/76214#comments</comments>
		<pubDate>Thu, 16 Jun 2011 14:45:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76214</guid>
		<description><![CDATA[Acorda Therapeutics, Inc. (ACOR) recently reported an analysis of data on Ampyra (dalfampridine) at the Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. The analysis demonstrated improvements in walking ability of patients on Ampyra as measured by patient self-report on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12). The analysis comprised data from a phase II trial and two phase III trials of Ampyra. These data were a part of Acorda’s new drug application (NDA) submission to the US Food and Drug Administration (FDA) for the approval of the drug. At the CMSC meeting, another set of study data on Ampyra called – UTI (urinary tract infection) Incidence among MS Patients Treated with Dalfampridine 10 mg Twice Daily – was also presented. As the name suggests, the study evaluated the incidence ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/16/acor-acorda-therapeutics-gets-mixed-data-on-ampyra/76214/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Compan Gets Good News</title>
		<link>http://www.stockbloghub.com/2011/06/15/bmy-bristol-myers-squibb-compan-gets-good-news/74752</link>
		<comments>http://www.stockbloghub.com/2011/06/15/bmy-bristol-myers-squibb-compan-gets-good-news/74752#comments</comments>
		<pubDate>Wed, 15 Jun 2011 16:49:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74752</guid>
		<description><![CDATA[Bristol-Myers Squibb Company (BMY) received a boost when its blood-thinner Eliquis (apixaban) was cleared by the European Commission (EC) in 27 nations of the European Union (EU) for preventing venous thromboembolic events (VTE) in adults who have undergone elective hip or knee replacement surgery. The approval by the EC is the first approval for Eliquis, a new oral direct factor Xa inhibitor. Bristol-Myers has co-developed the drug with Pfizer (PFE). The approval was based on ADVANCE-2 and ADVANCE-3 studies which revealed that the drug was statistically superior to 40 mg once-daily Lovenox (enoxaparin) of Sanofi-Aventis (SNY) without increase in bleeding rates. The decision of the EC to approve Eliquis does not surprise us since the drug had won a positive recommendation from the Committee for Medicinal Products for Human Use ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/15/bmy-bristol-myers-squibb-compan-gets-good-news/74752/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Chemical Industry Outlook &#8211; May 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/05/13/eu-chemical-industry-outlook-may-2011-industry-outlook/73995</link>
		<comments>http://www.stockbloghub.com/2011/05/13/eu-chemical-industry-outlook-may-2011-industry-outlook/73995#comments</comments>
		<pubDate>Fri, 13 May 2011 20:25:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[ACC]]></category>
		<category><![CDATA[American Campus Communities Inc]]></category>
		<category><![CDATA[BAK]]></category>
		<category><![CDATA[Braskem S.A.]]></category>
		<category><![CDATA[Calgon Carbon Corporation]]></category>
		<category><![CDATA[CCC]]></category>
		<category><![CDATA[CE]]></category>
		<category><![CDATA[Celanese Corporation]]></category>
		<category><![CDATA[DD]]></category>
		<category><![CDATA[DOW]]></category>
		<category><![CDATA[Eastman Chemical Company]]></category>
		<category><![CDATA[EI DuPont de Nemours & Company]]></category>
		<category><![CDATA[EMN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Mitsubishi UFJ Financial Group Inc]]></category>
		<category><![CDATA[MTU]]></category>
		<category><![CDATA[PPG]]></category>
		<category><![CDATA[PPG Industries Inc.]]></category>
		<category><![CDATA[The Dow Chemical Company]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73995</guid>
		<description><![CDATA[Chemicals are generally used to make a wide variety of consumer goods and are also used in agriculture, manufacturing, construction, and service industries. The chemical industry itself consumes 26% of its own output. Major industrial customers include rubber and plastic products, textiles, apparel, petroleum refining, pulp and paper, and primary metals. The chemical industry has shown rapid growth for more than fifty years. The fastest-growing areas have involved the manufacture of synthetic organic polymers used as plastics, fibers and elastomers. Globally, the chemical industry is mainly concentrated in three areas of the world: Western Europe, North America and Japan. The European community is the largest producer, followed by the U.S. and Japan. Chemicals are a nearly $3 trillion global business, and the European Union (EU) and U.S. chemical companies are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/13/eu-chemical-industry-outlook-may-2011-industry-outlook/73995/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACOR) Acorda Therapeutics Reports Loss That Missed Expectations</title>
		<link>http://www.stockbloghub.com/2011/05/08/acor-acorda-therapeutics-reports-loss-that-missed-expectations/73532</link>
		<comments>http://www.stockbloghub.com/2011/05/08/acor-acorda-therapeutics-reports-loss-that-missed-expectations/73532#comments</comments>
		<pubDate>Sun, 08 May 2011 15:50:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73532</guid>
		<description><![CDATA[Acorda Therapeutics Inc. (ACOR) posted a loss of 2 cents per share for the first quarter of fiscal 2011, compared with a loss of 56 cents in the year-ago period. The Zacks Consensus Earnings Estimate for the quarter was 18 cents per share. Despite increased revenues, higher operating expenses resulted in a loss during the quarter. Quarterly Details Quarterly revenues saw a whopping 245.3% increase to reach $61.3 million, with Ampyra sales exceeding expectations. However, revenues missed the Zacks Consensus Estimate of $65 million. Fourth quarter revenues comprised $58.9 million (up 282.9%) in product sales and $2.4 million (flat year over year) in license and royalty revenue. Sales of Ampyra, which was launched in March 2010, came in at $46.8 million. Ampyra, aimed at improving walking speed in multiple sclerosis ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/08/acor-acorda-therapeutics-reports-loss-that-missed-expectations/73532/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

